The Supreme Court’s current term ends in weeks, and corporate America is bracing for a volley of rulings that could raise drug prices, reshape energy litigation, and test whether any federal agency can punish phone carriers for selling customers’ location data. At least five major business disputes remain on the docket, most expected by late June or early July 2026, and each one carries stakes that extend well beyond the parties in the courtroom.
The term has already delivered a jolt. On April 22, 2026, a unanimous Court ruled that Michigan Attorney General Dana Nessel’s lawsuit seeking to shut down a segment of Enbridge’s Line 5 pipeline belongs in state court, not federal court. Nessel filed the case in 2019, invoking state environmental and public-trust laws tied to the aging pipeline that runs beneath the Straits of Mackinac. Line 5 has been in service since 1953, and environmental groups have long warned that a rupture could devastate the Great Lakes. By rejecting Enbridge’s bid to move the dispute to federal court, the justices placed the pipeline’s fate in a forum where state environmental statutes carry greater weight and where juries may be more receptive to pollution claims.
Energy litigation lands in two different courts
The Line 5 decision looks even more consequential alongside the Court’s handling of Chevron U.S.A. v. Plaquemines Parish, a case that opened a new path for oil and gas companies to shift Louisiana coastal-erosion lawsuits into federal court. (Key details of the Plaquemines Parish opinion, including the vote breakdown, had not been independently confirmed as of early May 2026.) Read together, the two outcomes show the justices drawing precise procedural lines rather than writing broad jurisdictional rules. For the energy industry, the distinction is enormous: state courts and federal courts apply different legal standards, draw from different jury pools, and produce different settlement dynamics. Pipeline operators weighing capital projects and producers facing environmental claims will need to map their litigation exposure venue by venue, a process that just got more complicated.
Phone carriers face a privacy reckoning
Wireless customers rarely think about who can see where they are at any given moment, but a case argued this term could determine whether anyone is watching the watchers. The Court heard oral arguments in a challenge to the Federal Communications Commission’s authority to impose forfeiture penalties on Verizon and AT&T for selling and sharing customers’ real-time location data without meaningful consent. According to the official Supreme Court oral-argument transcript, justices from both ideological wings pressed the carriers on the scope of the FCC’s penalty power, with pointed questions suggesting skepticism toward the industry’s position.
If that skepticism holds, major carriers could face tens of millions of dollars in proposed fines, a figure drawn from the FCC’s own enforcement notices. The case arrives at a moment when Congress has repeatedly failed to pass comprehensive federal privacy legislation, leaving agency enforcement as the primary check on how carriers handle sensitive personal data. For the more than 300 million wireless subscribers in the United States, according to CTIA industry data, the practical question is straightforward: if the FCC cannot penalize carriers for selling location data, who can?
Corporate liability for human-rights abuses abroad
Cisco Systems v. Doe I has drawn attention from technology and manufacturing firms that sell products or services to foreign governments. Plaintiffs allege that Cisco helped build surveillance infrastructure the Chinese government used to identify and persecute Falun Gong practitioners. The case turns on the reach of two federal statutes, the Alien Tort Statute and the Torture Victim Protection Act, that have historically allowed foreign nationals to sue in American courts over grave abuses committed overseas.
The Office of the Solicitor General filed a merits-stage amicus brief urging the Court to narrow liability, warning that an expansive reading could complicate U.S. foreign policy and diplomatic relationships. A ruling in Cisco’s favor would offer a measure of legal certainty to companies operating in countries with poor human-rights records. A ruling that preserves broader liability would signal that American courts remain open to claims of corporate complicity, raising compliance costs and reputational exposure across the global tech supply chain. Lower courts have split on how far these statutes reach, which is precisely why the justices took the case.
Pesticide preemption and the patchwork problem
Monsanto Co. v. Durnell asks a question that matters to every company selling an EPA-regulated product: does federal approval of a pesticide’s label shield the manufacturer from state-law failure-to-warn and design-defect claims? The case centers on the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA), which governs how pesticides are labeled and marketed. The Justice Department’s brief argues that the EPA’s label-approval process should carry significant preemptive weight.
Chemical and agricultural companies say that once the EPA has signed off on a product’s labeling and risk profile, they should not face a state-by-state patchwork of jury verdicts reaching contradictory conclusions about the same product. Plaintiffs and state officials counter that federal oversight has documented gaps and that tort liability remains a critical safety net, particularly for farmworkers and rural communities exposed to chemicals over years or decades. A broad preemption ruling could insulate manufacturers from thousands of pending state claims. A narrow one could open the door to more.
Generic drugs and the skinny-label gamble
For consumers, no pending case may matter more at the pharmacy counter than Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. (No. 24-889). The dispute involves Vascepa, a cardiovascular drug, and whether a generic drugmaker’s use of a “skinny label” can constitute induced patent infringement. Under current FDA practice, generic companies may carve patented indications off their labels, allowing them to sell a drug for its non-patented uses and bring cheaper alternatives to market. The generic drug industry has relied on this carve-out strategy for years to accelerate launches.
If the Court rules that skinny labels still expose generic manufacturers to inducement liability, companies may delay product launches or avoid certain drugs altogether. The case docket reflects the breadth of concern: pharmacy benefit managers, patient advocacy groups, and trade associations have all filed briefs. No oral-argument date or decision has been publicly confirmed as of May 2026. The Association for Accessible Medicines, the generic industry’s main trade group, has estimated that generic and biosimilar drugs save the U.S. health system hundreds of billions of dollars annually. While no public estimate isolates the specific consumer savings at risk in the Vascepa dispute alone, industry briefs warn that a ruling against skinny labels could discourage generic entry across a range of drugs, compounding costs for patients and insurers well beyond a single product.
What these rulings mean for the next wave of corporate risk
Across these five disputes, a pattern is visible: the Court is making fine-grained procedural and statutory distinctions rather than announcing sweeping doctrinal shifts. The split between the Line 5 and Plaquemines Parish outcomes is the clearest example. Both involve energy companies and environmental claims, yet the procedural results point in opposite directions, each driven by specific statutory text and factual details. That incremental approach may frustrate advocates who want bright-line rules, but it also means the real-world effects of each decision will depend heavily on how lower courts interpret the opinions in the months ahead.
For corporate legal departments, the takeaway from this term is that risk cannot be managed by watching a single case. Companies will need to reassess exposure on multiple fronts at once: where their disputes will be heard, how aggressively regulators can fine them, whether foreign plaintiffs can reach them in U.S. courts, how far federal product approvals shield them from state tort suits, and whether patent protections can block generic competitors even when those competitors follow the FDA’s own labeling rules. The answers are due before the justices leave Washington for their summer recess, and the consequences will shape boardroom calculations for years to come.
